CTOs on the Move

Infinity Pharmaceuticals

www.infi.com

 
Infinity Pharmaceuticals is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.infi.com
  • 780 Memorial Dr
    Cambridge, MA USA 02139
  • Phone: 617.453.1000

Executives

Name Title Contact Details

Funding

Infinity Pharmaceuticals raised $20M on 01/09/2020
Infinity Pharmaceuticals raised $92M on 02/12/2021

Similar Companies

Cytokine PharmaSciences

Cytokine PharmaSciences is a King Of Prussia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AiLife Diagnostics

AiLife Diagnostics is a CAP/CLIA laboratory that provides end-to-end genomic testing, interpretation services, and NGS analysis tool.

Akero Therapeutics

Akero Therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.

Brammer Bio

Brammer Bio is focused on providing clinical and commercial supply of autologous and allogeneic cell therapies, and viral vector products for in vivo and ex vivo therapeutic applications. Along with process and analytical development and regulatory support we enable large pharma and biotech clients to accelerate the delivery of novel medicines and improve patient health. Brammer Bio occupies 45,000 ft2 of process development and phase I/II clinical manufacturing space in Alachua, FL, and is developing a 50,000 ft2 facility in Lexington, MA, with plans to build-out large-scale, phase III/commercial ready viral vector manufacturing suites, segregated cell and gene therapy suites, and QC and analytical laboratories for clinical and commercial launch services.

Arno Therapeutics, Inc.

Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors.